Heat shock protein-90 inhibitors: A chronicle from geldanamycin to today's agents

Current Opinion in Investigational Drugs

Volumn 7, Issue 6, 2006, Pages 534-541

  Chiosis, Gabriela ^a   Lopes, Eloisi Caldas ^a   Solit, David ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Ansamycins; Anticancer therapeutics; Hsp90; PU class Hsp90 inhibitors; Pyrazoles; Radicicol and derivatives

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DIMETHYLLAMINO 17 DEMETHOXYGELDANAMYCIN; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANSAMYCIN DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CNF 1010; COUMARIN DERIVATIVE; CYCLOPROPARADICICOL; FR 901228; G 3130; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; KF 55823; KOS 953; LBH 589; MONOCLONAL ANTIBODY; MYCOGRAB; NOVOBIOCIN; POCHONIN D; PU 24 FCI; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; RADICICOL; RESORCINOL DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VER 49009; ZERANOL;

ACETYLATION; AMINO TERMINAL SEQUENCE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL SURVIVAL; CELL TRANSFORMATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL HEMORRHAGE; GROWTH INHIBITION; HUMAN; LIVER DISEASE; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BINDING, COMPETITIVE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINONES; TRIAZOLES;

EID: 33745174538     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Oppermann H, Levinson AD, Levintow L, Varmus HE, Bishop JM, Kawai S: Two cellular proteins that immunoprecipitate with the transforming protein of Rous sarcoma virus. Virology (1981) 113(2):736-751.
2. Xu Y, Lindquist S: Heat-shock protein Hsp90 governs the activity of pp60v-src kinase. Proc Natl Acad Sci USA (1993) 90(15):7074-7078.
3. Neckers L, Neckers K: Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs (2005) 10(1):137-149.
4. Workman P: Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett (2004) 206(2):149-157.
5. Whitesell L, Lindquist SL: Hsp90 and the chaperoning of cancer. Nat Rev Cancer (2005) 5(10):761-772.
6. Chiosis G: Targeting chaperones in transformed systems - a focus on Hsp90 and cancer. Expert Opin Ther Targets (2006) 10(1):37-50.
7. Wegele H, Muller L, Buchner J: Hsp70 and Hsp90 - a relay team for protein folding. Rev Physiol Biochem Pharmacol (2004) 151:1-44.
8. Neckers L, Schulte TW, Mimnaugh E: Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs (1999) 17(4):361-373.
9. Schulte TW, Neckers LM: The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to Hsp90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol (1998) 42(4):273-279.
10. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM: Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: Effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol (2005) 56(2):126-137.
11. Soga S, Shiotsu Y, Akinaga S, Sharma SV: Development of radicicol analogues. Curr Cancer Drug Targets (2003) 3(5):359-369.
12. Yamamoto K, Garbaccio RM, Stachel SJ, Solit DB, Chiosis G, Rosen N, Danishefsky SJ: Total synthesis as a resource in the discovery of potentially valuable antitumor agents: Cycloproparadicicol. Angew Chem Int Ed Engl (2003) 42(11):1280-1284.
13. Moulin E, Zoete V, Barluenga S, Karplus M, Winssinger N: Design, synthesis, and biological evaluation of Hsp90 inhibitors based on conformational analysis of radicicol and its analogues. J Am Chem Soc (2005) 127(19):6999-7004.
14. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N: A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol (2001) 8(3):289-299.
15. Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N: Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets (2003) 3(5):371-376.
16. Dymock B, Barril X, Beswick M, Collier A, Davies N, Drysdale M, Fink A, Fromont C, Hubbard RE, Massey A, Surgenor A et al: Adenine derived inhibitors of the molecular chaperone Hsp90-SAR explained through multiple X-ray structures. Bioorg Med Chem Lett (2004) 14(2):325-328.
17. Cheung KM, Matthews TP, James K, Rowlands MG, Boxall KJ, Sharp SY, Maloney A, Roe SM, Prodromou C, Pearl LH, Aheme GW et al: The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett (2005) 15(14):3338-3343.
18. Dymock BW, Barril X, Brough PA, Cansfield JE, Massey A, McDonald E, Hubbard RE, Surgenor A, Roughley SD, Webb P, Workman P et al: Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem (2005) 48(13):4212-4215.
19. Kreusch A, Han S, Brinker A, Zhou V, Choi HS, He Y, Lesley SA, Caldwell J, Gu XJ: Crystal structures of human Hsp90α-complexed with dihydroxyphenylpyrazoles. Bioorg Med Chem Lett (2005) 15(5):1475-1478.
20. Uehara Y: Natural product origins of Hsp90 inhibitors. Curr Cancer Drug Targets (2003) 3(5):325-330.
21. Stebbins CE, Russo AA, Schneider G Rosen N, Hartl U, Pavletich NP: Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell (1997) 89(2):239-250.
22. Mimnaugh EG, Chavany C, Neckers L: Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein tyrosine kinase induced by geldanamycin. J Biol Chem (1996) 271(37):22796-22801.
23. Schulte TW, Neckers LM: The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to Hsp90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol (1998) 42(4):273-279.
24. Solit DB, Zhang FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI et al: 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 8(5):986-993.
25. De Candia P, Solit D, Giri D, Brogi E, Siegel PM, Olshen AB, Muller WJ, Rosen N, Benezra R: Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/ neu-dependent breast tumors. Proc Natl Acad Sci USA (2003) 100(21):12337-12342.
26. Sausville EA, Tomaszewski JE, Ivy P: Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets (2003) 3(5):377-383.
27. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M et al: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol (2005) 23(18):4152-4161.
28. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brulsky AM et al: Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res (2005) 11(9):3385-3391.
29. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S et al: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol (2005) 23(6):1078-1087.
30. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM: Comparison of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: Effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmaco (2005) 56(2):126-137.
31. Cysyk RL, Parker RJ, Barchi JJ Jr, Steeg PS, Hartman NR, Strong JM: Reaction of geldanamycin and C17-substituted analogues with glutathione: Product identifications and pharmacological implications. Chem Res Toxicol (2006) 19(3):376-381.
32. Zhang H, Neely LS, Yang Y-C, Burrows FJ: Influence of muldidrug resistance proteins on the antitumor activity of natural and synthetic Hsp90 inhibitors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications (2005):Abs C39.
33. Madden T-A, Pumford S, Barrow D, Dutkowski CM, McClelland R, Nicholson RI: Development of acquired resistance to 17(allylamino)-17-demethoxygeldanamycin (17-AAG) in hormone refractory breast cancers in vitro. Proc Amer Assoc Cancer Res (2005) 96:Abs LB-267.
34. 1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood (2000) 96(6):2284-2291
35. Shen G, Blagg BS: Radester, a novel inhibitor of the Hsp90 protein folding machinery. Org Lett (2005) 7(11):2157-2160.
36. Vilenchik M, Solit D, Basso M, Huezo H, Lucas B, Huazhong H, Rosen N, Spampinato C, Modrich P, Chiosis G: Targeting wide-range oncogenic transformation via PU24FCI, a specific inhibitor of tumor Hsp90. Chem Biol (2004) 11(6):787-797.
37. Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies P, Chiosis G: Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem (2005) 48(8):2892-2905.
38. He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino RM, Gewirth DT, Chiosis G: Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem (2006) 49(1):381-390.
39. Biamonte MA, Shi J, Hong K, Hurst DC, Zhang L, Fan J, Busch DJ, Karjian PL, Maldonado AA, Sensintaffar JL, Yang YC et al: Orally active purine-based inhibitors of the heat shock protein 90. J Med Chem (2006) 49(2):817-828.
40. Chiosis G. Design and development of purine-scaffold inhibitors of the heat shock protein 90. ACS (2006) 231:Abs MEDI-206.
41. Kantarjian H. A phase I dose escalation study of CNF2024 for ZAP-70 positive CLL. MD Anderson Leukemia Insights Newsletter (2005) 10 (3). http://www.mdanderson.org/publications/insights/
42. Serenex Inc: Serenex Inc: Pipeline. Company World Wide Web Site (2005):May 13.
43. Marcu MG, Schulte TW, Neckers L: Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst (2000) 92(3):242-248.
44. Yu XM, Shen G, Neckers L, Blake H, Holzbeierlein J, Cronk B, Blagg BS: Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc (2005) 127(37):12778-12779.
45. Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB: Regulation of the dynamics of Hsp90 action on the glucocorticoid receptor by acetylation/ deacetylation of the chaperone. J Biol Chem (2005) 280(40):33792-33799.
46. Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G: Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res (2003) 63(23):8241-8247.
47. Martinez-Ruiz A, Villanueva L, Gonzalez de Orduna C, Lopez-Ferrer D, Higueras MA, Tarin C, Rodriguez-Crespo I, Vazquez J, Lamas S: S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Natl Acad Sci USA (2005) 102(24):8525-8530.
48. Aoyagi S, Archer TK: Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol (2005) 15(11):565-567.
49. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst (2002) 94(7):504-513.
50. Budillon A, Bruzzese F, Di Gennaro E, Caraglia M: Multiple-target drugs: Inhibitors of heat shock protein 90 and of histone deacetylase. Curr Drug Targets (2005) 6(3):337-351.
51. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E et al: Inhibition of histone deacetylase 8 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 280(29):26729-28734.
52. NeuTec Pharma plc: NeuTec Pharma commences patient recruitment in breast cancer clinical trial using its lead drug Mycograb. Press Release (2005):September 19.
53. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI et al: Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 7(5):457-468.